543 related articles for article (PubMed ID: 27916620)
21. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
Siddiqui MK; Shukla P; Jenkins M; Ouwens M; Guranlioglu D; Darken P; Biswas M
Ther Adv Respir Dis; 2019; 13():1753466619894502. PubMed ID: 31868101
[TBL] [Abstract][Full Text] [Related]
22. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C
Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537
[TBL] [Abstract][Full Text] [Related]
23. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.
De Backer W; De Backer J; Vos W; Verlinden I; Van Holsbeke C; Clukers J; Hajian B; Siddiqui S; Jenkins M; Reisner C; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():2673-2684. PubMed ID: 30214185
[TBL] [Abstract][Full Text] [Related]
24. Randomized study of the effects of Aerochamber Plus
Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P
Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869
[TBL] [Abstract][Full Text] [Related]
27. Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials.
Zheng J; Xu JF; Jenkins M; Assam PN; Wang L; Lipworth BJ
Respir Res; 2020 Mar; 21(1):69. PubMed ID: 32164675
[TBL] [Abstract][Full Text] [Related]
28. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.
Rabe KF
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):685-698. PubMed ID: 28443352
[TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
[TBL] [Abstract][Full Text] [Related]
30. 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD.
Reisner C; Gottschlich G; Fakih F; Koser A; Krainson J; Delacruz L; Arora S; Feldman G; Pudi K; Siddiqui S; Orevillo C; Maes A; St Rose E; Martin U
Respir Res; 2017 Aug; 18(1):157. PubMed ID: 28821260
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
Muro S; Sugiura H; Darken P; Dorinsky P
Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
[TBL] [Abstract][Full Text] [Related]
33. Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study.
Kerwin EM; Ferguson GT; Mo M; DeAngelis K; Dorinsky P
Respir Res; 2019 Jul; 20(1):167. PubMed ID: 31358008
[TBL] [Abstract][Full Text] [Related]
34. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M
Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340
[TBL] [Abstract][Full Text] [Related]
35. Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability.
Doty A; Schroeder J; Vang K; Sommerville M; Taylor M; Flynn B; Lechuga-Ballesteros D; Mack P
AAPS PharmSciTech; 2018 Feb; 19(2):837-844. PubMed ID: 29019170
[TBL] [Abstract][Full Text] [Related]
36. Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.
Fukushima Y; Nakatani Y; Ide Y; Sekino H; St Rose E; Siddiqui S; Maes A; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1187-1194. PubMed ID: 29695902
[TBL] [Abstract][Full Text] [Related]
37. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Reisner C; Dorinsky P
Respir Med; 2019; 158():59-66. PubMed ID: 31605923
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study.
Chen Q; Hu C; Yu H; Shen K; Assam PN; Gillen M; Liu Y; Dorinsky P
Clin Ther; 2019 May; 41(5):897-909.e1. PubMed ID: 30982547
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
40. Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults.
Dorinsky P; DePetrillo P; DeAngelis K; Trivedi R; Darken P; Gillen M
Clin Ther; 2020 Apr; 42(4):634-648. PubMed ID: 32253054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]